

## Summary of Product Characteristics

### 1 NAME OF THE MEDICINAL PRODUCT

Fluphegood 25 mg/ml Solution for Injection

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of solution contains 25mg Fluphenazine decanoate (250mg/10ml)

Excipients: contains 15mg benzyl alcohol (E1519) per ml and sesame oil.

For a full list of excipients, see section 6.1.

### 3 PHARMACEUTICAL FORM

Solution for injection (Injection)

A clear yellow, oily solution.

### 4 CLINICAL PARTICULARS

#### 4.1 Therapeutic Indications

In the long-term management of psychotic disorders such as chronic schizophrenia, the disturbed elderly, severe anxiety tension states and personality disorders.

Fluphegood is not intended for use in nonpsychotic disorders or for short-term therapy (< 3 months).

Fluphegood has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

#### 4.2 Posology and method of administration

##### Adults:

The usual initial dose is 12.5mg but in the elderly this dose should be 6.25mg. Subsequent dosage is usually 25mg every two to four weeks, with a range of 12.5 to 100mg depending on the patient's response. In those with no previous therapy, treatment can be initiated by the oral route or using a quick-acting agent before transferring to this form.

Dosage should not exceed 100 mg. If doses greater than 50 mg are deemed necessary, the next dose and succeeding doses should be increased cautiously in increments of 12.5 mg.

Severely agitated patients may be treated initially with a rapid-acting phenothiazine compound such as fluphenazine hydrochloride injection. When acute symptoms subsided, 25 mg ( 1mL ) of Fluphegood may be administered; subsequent dosage is adjusted as necessary.

##### Elderly:

Elderly patients may be particularly susceptible to extrapyramidal reactions. Therefore reduced maintenance dosage may be required and a smaller initial dose (see above).

##### Children:

Not recommended for children.

**Note:** The dosage should not be increased without close supervision and it should be noted that there is a variability in individual response.

The response to antipsychotic drug treatment may be delayed. If drugs are withdrawn, recurrence of symptoms may not become apparent for several weeks or months.

### **4.3 Contraindications**

Comatose states

Suspected or established subcortical brain damage

Marked cerebral atherosclerosis

Phaeochromocytoma

Renal

failure

Liver

failure

Severe cardiac insufficiency

Severely depressed states

Hypersensitivity to any of the ingredients of the formulation

Patients receiving large doses of CNS depressants (e.g. alcohol, barbiturates, narcotics, hypnotics etc.)

Existing blood dyscrasias

Caution should be observed in patients with a history of sensitivity to other phenothiazines, as cross-sensitivity may occur.

### **4.4 Special warnings and precautions for use**

Caution should be exercised in patients with the following conditions:

Liver disease

Cardiac arrhythmias, mitral insufficiency, risk factors for stroke or cardiovascular disease or family history of QT prolongation

Thyrotoxicosis

Severe respiratory disease

Parkinson's disease

Patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.

Personal or family history of narrow angle glaucoma

In very hot weather

The elderly, particularly if frail or at risk of hypothermia

Hypothyroidism

Myasthenia gravis

Prostatic

hypertrophy

Patients exposed to extreme heat or phosphorus insecticides; in patients with a history of convulsive disorders (since grand mal convulsions have been known to occur in patients on therapy with fluphenazine).

Avoid concomitant antipsychotics.

Patients taking this medication should carry a treatment card indicating dosage received.

Patients undergoing surgery should be carefully monitored for possible hypotensive phenomena and the doses of anaesthetics or other CNS depressant used may need to be reduced (see sections 4.3 and 4.5).

During the first months of treatment routine blood count and liver function tests are advisable as blood dyscrasia (including leukopenia, agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura, eosinophilia, and pancytopenia) and liver dysfunction may occur. Furthermore, if any soreness of the mouth, gums, or throat, or any symptoms of upper respiratory infection occur and confirmatory leukocyte count indicates bone marrow depression, therapy should be discontinued and other appropriate measures instituted immediately.

This product contains 15 mg of benzyl alcohol per ml. Benzyl alcohol must not be given to premature babies or neonates. It may cause toxic reactions and anaphylactoid reactions in infants and children up to three years old.

This product contains sesame oil which may rarely cause severe allergic reactions.

Potential of the effects of alcohol may occur with the use of this drug (see section 4.3).

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Fluphegood, and preventive measures undertaken.

As with any phenothiazine, the physician should be alert to the possible development of pneumonia in patients under prolonged treatment with fluphenazine decanoate.

#### Patients at Risk

Patients with a known hypersensitivity to phenothiazines should be carefully monitored if fluphenazine is given. Patients with symptoms such as depression, confusion, or weight loss, should be carefully evaluated to exclude a diagnosis of atypical mood disorders before initiating treatment with fluphenazine. When the pharmacologic effects and an appropriate dosage are apparent, an equivalent dose of Fluphegood Injection may be administered. Subsequent dosage adjustments are made in accordance with the response of the patient (see section 4.2).

#### Increased Mortality in Elderly people with Dementia

Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.

Fluphegood is not licensed for the treatment of dementia-related behavioural disturbances.

#### Abrupt Withdrawal

In general, phenothiazines do not produce psychic dependence; however, gastritis, nausea and vomiting, dizziness, and tremulousness have been reported within 2 to 4 days following abrupt cessation of high-dose therapy and have been reported to subside in 1 to 2 weeks. Reports suggest that these symptoms can be reduced by gradual reduction of the dosage or by continuing concomitant anti-Parkinson agents for several weeks after the phenothiazine is withdrawn (see sections 4.5 and 4.8).

Neuroleptics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic neuroleptic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to neuroleptic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically (see sections 4.4 and 4.8).

### **4.5 Interaction with other medicinal products and other forms of interaction**

*Antihypertensives:* The antihypertensive action of guanethidine, clonidine and possibly other adrenergic-blocking antihypertensive agents may be blocked. Clonidine may decrease the antipsychotic activity of phenothiazines.

*Medicines that prolong the QT Interval:* Medicines that can prolong the QT interval should be avoided, as should any medicine that can cause electrolyte imbalance or an increase in the concentration of fluphenazine in the blood. (See section 4.4)

*P450 Enzyme substrates or inhibitors:* Fluphenazine is metabolized by P450 2D6 and is itself an inhibitor of this drug-metabolizing enzyme. The plasma concentrations and the effects of fluphenazine may, therefore, be increased and prolonged by drugs that are either the substrates or inhibitors of this P450 isoform, possibly resulting in cardiac toxicity, anticholinergic side effects, or orthostatic hypotension.

Examples of drugs which are substrates or inhibitors of cytochrome P450 2D6 include anti-arrhythmics, certain antidepressants including SSRIs and tricyclics, certain antipsychotics,  $\beta$ -blockers, protease inhibitors, opiates, cimetidine and ecstasy (MDMA). This list is not exhaustive.

*CNS Depressants/Alcohol/Analgesics:* The patient's response to alcohol and other CNS depressants, such as hypnotics, sedatives or strong analgesics, may be exaggerated while taking Fluphegood. Combined use with narcotic analgesics may cause hypotension as well as CNS or respiratory depression (see sections 4.3 and 4.4).

*Tricyclic Antidepressants:* Phenothiazines impair the metabolism of tricyclic antidepressants. Serum concentrations of both the tricyclic and phenothiazine are increased. Sedative and antimuscarinic effects may be potentiated or prolonged. Tricyclics may increase potential for arrhythmia.

*Lithium:* Neurotoxicity has been reported when lithium is used concomitantly with fluphenazine

*ACE inhibitors/Thiazide Diuretics:* Hypotension may result via additive or synergistic pharmacological activity.

*Beta Blockers:* Plasma levels of both drugs may be increased. Dosage reduction of both drugs is recommended.

*Metrizamide:* Phenothiazines may predispose patients to metrizamide-induced seizures. Discontinue fluphenazine decanoate for 48 hours prior to and for at least 24 hours after myelography.

*Epinephrine and other sympathomimetics:* Phenothiazines may antagonize the action of adrenaline and other sympathomimetics and may cause severe hypotension.

*Levodopa:* Phenothiazines may impair the anti-Parkinson effect of L-Dopa.

*Anticholinergics/Antimuscarinics:* Cholinergic blockade may be exaggerated when Fluphegood is administered with anticholinergic agents, especially in older patients. Antimuscarinic effects may be potentiated or prolonged. Close supervision and careful dosage adjustment are required when Fluphegood is used with other anticholinergic or antimuscarinic drugs.

*Anticonvulsants:* Anticonvulsant action may be impaired by Fluphegood

*Anticoagulants:* Phenothiazines may alter the effects of anticoagulants.

*Antidiabetics:* Phenothiazines have been associated rarely with loss of blood glucose control in patients with diabetes.

*Monoamine oxidase inhibitors:* Fluphegood may increase the effect of monoamine oxidase inhibitors

*Quinidine and other anti-arrhythmics:* the cardiac- depressant effects may be enhanced by phenothiazines.

*Corticosteroids, digoxin and neuromuscular blocking agents:* the absorption of these drugs may be enhanced by phenothiazines

#### **4.6 Fertility, pregnancy and lactation**

Phenothiazine should only be used during pregnancy if it is considered essential by the physician.

Neonates exposed to antipsychotics including Fluphegood during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and /or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully. The lowest possible dose should be administered for the shortest duration.

##### Breast-feeding

Since the drug is excreted in breast milk it should not be used during lactation in women who are breast-feeding.

#### **4.7 Effects on ability to drive and use machines**

Phenothiazines may induce drowsiness. Persons taking these drugs should not drive or operate machinery unless the drug has been shown not to interfere with physical or mental ability.

#### **4.8 Undesirable effects**

The adverse events reported most frequently with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia. Most often these extrapyramidal symptoms are reversible; however, they may be persistent. With any given phenothiazine derivative, the incidence and severity of such events depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants.

Acute dystonic reactions occur infrequently, as a rule within the first 24-48 hours, although delayed reactions

may occur. In susceptible individuals they may occur after only small doses. These may include such dramatic manifestations as oculogyric crises and opisthotonos. They are rapidly relieved by intravenous administration of an anti-Parkinsonian agent such as procyclidine.

Parkinsonian-like states may occur particularly between the second and fifth days after each injection, but often decrease with subsequent injections. These reactions may be reduced by using smaller doses more frequently, or by the concomitant use of anti-Parkinsonian drugs such as benhexol, benztropine or procyclidine. Anti-Parkinsonian drugs should not be prescribed routinely, because of the possible risks of aggravating anticholinergic side effects or precipitating toxic confusional states, or of impairing therapeutic efficacy.

With careful monitoring of the dose the number of patients requiring anti-Parkinsonian drugs can be minimised. Tardive dyskinesia

Tardive dyskinesia, a syndrome characterised by involuntary dyskinetic movements, may develop in patients on antipsychotic therapy and occasionally even in those who have discontinued or never received such treatment. Those at particular risk include the elderly, females and patients on high dosage or prolonged therapy, i.e. with a high total cumulative dose. Nonetheless, the syndrome can develop without such factors being involved. The syndrome may be irreversible, or only slowly reversed if neuroleptic treatment is withdrawn. Fine, vermicular movements of the tongue are reported to be an early sign and if the medication is discontinued the syndrome may not progress.

In an attempt to minimise the possibility of the development of such a syndrome, major tranquilliser therapy should be reserved for patients for whom it is essential, the dosage used should be the lowest commensurate with optimal benefit, and duration of treatment should not extend beyond that necessary for the patient.

There is no known treatment for tardive dyskinesia. The antipsychotic drug may mask it, as may anticholinergic agents.

### Neuroleptic Malignant Syndrome

The potentially fatal syndrome may occur with use of any neuroleptic agents. Symptoms include clouding of consciousness, rigidity and other extrapyramidal effects, and autonomic dysfunction (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias), most importantly hyperpyrexia. Leukocytosis, fever, elevated CPK, liver function abnormalities, and acute renal failure may also occur with NMS. Treatment involves the immediate cessation of neuroleptic therapy, intensive symptomatic management and monitoring as appropriate and treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored since recurrences of NMS have been reported. Others

Blood dyscrasias, including agranulocytosis, have been reported with phenothiazine derivatives, which may increase the potential susceptibility to infection. Blood counts should be performed if the patient develops signs of persistent infection. Transient leucopenia and thrombocytopenia have been reported (see section 4.4). Antinuclear antibodies and SLE have been reported very rarely.

A transient rise in serum cholesterol has been reported in patients on oral fluphenazine.

Fever, vomiting, systemic lupus erythematosus like syndrome, altered ECG tracings, liver or kidney damage, abnormal skin pigmentation and lens opacities, including cataracts, have sometimes been seen following long-term administration of high doses of phenothiazines (see section 4.4). There have been reports of retinopathy, pigmentary retinal deposits in patients receiving fluphenazine at high doses or for prolonged periods.

Hypotension has rarely presented a problem with fluphenazine. However, patients with pheochromocytoma, cerebral vascular or renal insufficiency, or a severe cardiac reserve deficiency (such as mitral insufficiency) appear to be particularly prone to hypotensive reactions with phenothiazine compounds, and should, therefore, be observed closely when the drug is administered. If severe hypotension should occur, supportive measures, including the use of intravenous vasopressor drugs, should be instituted immediately. Levarterenol bitartrate injection is the most suitable drug for this purpose; epinephrine should NOT be used, since phenothiazine

derivatives have been found to reverse its action, resulting in a further lowering of blood pressure.

Elderly patients may be more susceptible to the sedative and hypotensive effects.

The effects of phenothiazines on the heart are dose-related. ECG changes, with prolongation of the QT interval and T-wave changes, have been reported commonly in patients treated with moderate to high dosage; they are reversible on reducing the dose. In a very small number of cases, they have been reported to precede serious arrhythmias, including ventricular tachycardia and fibrillation, which have also occurred after overdosage. Sudden, unexpected and unexplained deaths have been reported in hospitalised psychotic patients receiving phenothiazines. Cardiac arrest and torsades de pointes have been reported with anti-psychotic agents.

Phenothiazines may impair body temperature regulation. Cases of severe hypothermia or hyperpyrexia have been reported in association with moderate or high dosage of phenothiazines.

Elderly or hypothyroid patients may be particularly susceptible to hypothermia. The hazard of hyperpyrexia may be increased by especially hot or humid weather, or by drugs such as anti-Parkinsonian agents, which impair sweating.

Hormonal effects of fluphenazines include hyperprolactinaemia, which may cause galactorrhoea, gynaecomastia and oligo- or amenorrhoea. Sexual function may be impaired.

Oedema has been reported with phenothiazine medication.

Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs – Frequency unknown.

Pregnancy, puerperium and perinatal conditions -drug withdrawal syndrome neonatal not known ( see section 4.6)

The list below is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common ( $\geq 1/10$ ), common ( $\geq 1/100, < 1/10$ ), uncommon ( $\geq 1/1000, < 1/100$ ), rare ( $\geq 1/10000, < 1/1000$ ), very rare ( $< 1/10000$ ), and not known (cannot be estimated from the available data). .

<b>MedDRA SOC</b>	<b>MedDRA Preferred Term</b>	<b>Frequency</b>
<b>Infections and infestations</b>	<b>Upper respiratory tract infection</b>	Not known
<b>Blood and lymphatic system disorders</b>	<b>Pancytopenia</b>	Not known
	<b>Agranulocytosis</b>	Not known
	<b>Thrombocytopenic purpura</b>	Not known
<b>Purpura non-thrombocytopenic</b>	Not known	
<b>Leukopenia</b>	Not known	
<b>Eosinophilia</b>	Not known	
<b>Immune system disorders</b>	<b>Anaphylactic reaction</b>	Not known
<b>Investigations</b>	<b>Pregnancy test false positive</b>	Not known
<b>Metabolism and nutrition disorders</b>	<b>Inappropriate antidiuretic hormone secretion</b>	

Not known

<b>Hyponatraemia</b>	Not known	
<b>Anorexia</b>	Not known	
<b>Weight fluctuation</b>	Not known	
<b>Psychiatric disorders</b>	<b>Restlessness</b>	Not known
<b>Agitation</b>	Not known	
<b>Abnormal dreams</b>	Not known	
<b>Nervous system disorders</b>	<b>Neuroleptic malignant syndrome</b>	Not known
<b>Cerebrovascular accident</b>	Not known	
<b>Brain oedema</b>	Not known	
<b>Tardive dyskinesia</b>	Not known	
<b>Extrapyramidal disorder</b>	Not known	
<b>Parkinsonism</b>	Not known	
<b>Dystonia</b>	Not known	
<b>Dyskinesia</b>	Not known	
<b>Akathisia</b>	Not known	
<b>Oculogyration</b>	Not known	
<b>Opisthotonos</b>	Not known	
<b>Hyperreflexia</b>	Not known	
<b>Choreoathetosis</b>	Not known	
<b>Somnolence</b>	Not known	
<b>Lethargy</b>	Not known	
<b>Electroencephalogram abnormal</b>	Not known	
	<b>Cerebrospinal fluid protein abnormal</b>	Not known
<b>Headache</b>	Not known	
<b>Eye disorders</b>	<b>Glaucoma</b>	Not known
<b>Vision blurred</b>	Not known	
<b>Lenticular opacities</b>	Not known	
<b>Corneal opacity</b>	Not known	
<b>Cardiac disorders</b>	<b>Cardiac arrest</b>	Not known
<b>Torsade de pointes</b>	Not known	
<b>Ventricular arrhythmia</b>	Not known	
<b>Ventricular fibrillation</b>	Not known	
	<b>Ventricular tachycardia</b>	Not known
	<b>Electrocardiogram QT prolonged</b>	Not known
	<b>Electrocardiogram abnormal</b>	Not known
<b>Vascular disorders</b>	<b>Hypertension</b>	Not known
<b>Blood pressure fluctuation</b>	Not known	
<b>Hypotension</b>	Not known	
<b>Thromboembolic disorders</b>	Not known	
<b>Respiratory, thoracic and mediastinal disorders</b>	<b>Asthma</b>	Not known

<b>Laryngeal oedema</b>	Not known	
<b>Nasal congestion</b>	Not known	
<b>Gastrointestinal disorders</b>	<b>Ileus paralytic</b>	Not known
<b>Faecaloma</b>	Not known	
<b>Dry mouth</b>	Not known	
<b>Constipation</b>	Not known	
<b>Salivary hypersecretion</b>	Not known	
<b>Oral pain</b>	Not known	
<b>Gingival pain</b>	Not known	
<b>Pharyngolaryngeal pain</b>	Not known	
<b>Nausea</b>	Not known	
<b>Vomiting</b>	Not known	
<b>Hepatobiliary disorders</b>	<b>Hepatitis</b>	Not known
<b>Jaundice cholestatic</b>	Not known	
<b>Jaundice</b>	Not known	
<b>Liver function test abnormal</b>	Not known	
<b>Hepatic function abnormal</b>	Not known	
<b>Skin and subcutaneous tissue disorders</b>	<b>Dermatitis exfoliative</b>	Not known
<b>Angioneurotic oedema</b>	Not known	
<b>Photosensitivity reaction</b>	Not known	
<b>Urticaria</b>	Not known	
<b>Seborrhoea</b>	Not known	
	<b>Erythema</b>	Not known
	<b>Eczema</b>	Not known
	<b>Hyperhidrosis</b>	Not known
	<b>Pruritus</b>	Not known
	<b>Pigmentation disorder</b>	Not known
<b>Musculoskeletal, connective tissue and bone disorders</b>	<b>Systemic lupus erythematosus</b>	Not known
	<b>Blood creatine phosphokinase increased</b>	Not known
<b>Renal and urinary disorders</b>	<b>Renal failure acute</b>	Not known
<b>Neurogenic bladder</b>	Not known	
<b>Polyuria</b>	Not known	
<b>Reproductive system and breast disorders</b>	<b>Gynaecomastia</b>	Not known
	<b>Menstruation irregular</b>	Not known
	<b>Lactation disorder</b>	Not known
	<b>Erectile dysfunction</b>	Not known
	<b>Libido disorder</b>	Not known
<b>General disorders and administration site condition</b>	<b>Sudden death</b>	Not known

**Oedema peripheral**

Not known

**Pyrexia**

Not known

---

---

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after Authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the National Regulatory Authority, Pharmacovigilance Electronic Reporting System (PvERS) <https://pv.pharmacyboardkenya.org/>

### 4.9 Overdose

In general, the symptoms of overdose are extensions of known pharmacologic effects and adverse reactions, the most prominent of which would be: 1) severe extrapyramidal reactions, 2) hypotension, or 3) sedation. CNS depression may progress to coma with areflexia. Restlessness, confusion and excitement may occur with early or mild intoxication. The drug should be withdrawn and the symptoms of overdose treated supportively. If severe hypotension should occur, supportive measures, including the use of intravenous vasopressor except for adrenaline are the most suitable drugs for this purpose. In case of severe extrapyramidal reactions, anti-Parkinson medication should be administered, and should be continued for several weeks. Anti-Parkinson medication should be withdrawn gradually to avoid the emergence of rebound extrapyramidal symptoms. Limited experience indicates that phenothiazines are not dialyzable. Hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis are ineffective in phenothiazine poisoning.

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Fluphenazine decanoate is an ester of the potent neuroleptic fluphenazine, a phenothiazine derivative of the piperazine type. The ester is slowly absorbed from the intramuscular site of injection and is then hydrolysed in the plasma to the active therapeutic agent, fluphenazine.

Extrapyramidal reactions are not uncommon, but fluphenazine does not have marked sedative or hypotensive properties.

### 5.2 Pharmacokinetic properties

A phenothiazine derivative, widely distributed, metabolised in the liver and excreted via kidney and entero biliary tract with a  $T_{1/2}$  of 2.5 weeks to 16 weeks.

### **5.3 Preclinical safety data**

No further information is available.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Benzyl alcohol (E1519)  
Sesame oil

### **6.2 Incompatibilities**

Not applicable

### **6.3 Shelf life**

Unopened: 1 year

Once opened: Use within 28 days of first opening. Discard any unused portion

### **6.4 Special precautions for storage**

Do not store above 25°C. Do not refrigerate or freeze. Keep vial in the outer carton to protect from light.

### **6.5 Nature and contents of container**

Type I amber glass vial (10ml), with white pharma gummi rubber stopper and aluminium seal. Each vial is packed in a cardboard carton with a leaflet.

### **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

Any unused medicine or waste material should be disposed of in accordance with local requirements.

MARKETING AUTHORISATION HOLDER

**GOODMED HEALTHCARE LTD**

**P.O BOX 76337, NAIROBI KENYA.**

## **7 MARKETING AUTHORISATION NUMBER**

### **7 Marketing Authorization Number:**

H2025/CTD12162/26268

### **9 Date of First <Registration> / Renewal of The <Registration>**

### **10 Date of Revision of the Text**

